MA32611B1 - Procedes de traitement de la thalassemie - Google Patents

Procedes de traitement de la thalassemie

Info

Publication number
MA32611B1
MA32611B1 MA33672A MA33672A MA32611B1 MA 32611 B1 MA32611 B1 MA 32611B1 MA 33672 A MA33672 A MA 33672A MA 33672 A MA33672 A MA 33672A MA 32611 B1 MA32611 B1 MA 32611B1
Authority
MA
Morocco
Prior art keywords
thalassemia
operations
treatment
therapeutic amount
effective therapeutic
Prior art date
Application number
MA33672A
Other languages
Arabic (ar)
English (en)
Inventor
John D Hood
Original Assignee
Targegen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41581108&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32611(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targegen Inc filed Critical Targegen Inc
Publication of MA32611B1 publication Critical patent/MA32611B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

L'invention concerne un procédé de traitement, d'amélioration ou de retardement d'au moins un symptôme d'une affection génétique du sang, par exemple une affection liée aux drépanocytes ou une thalassémie, chez un patient le nécessitant, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de jak2. Elle concerne également en partie un procédé de réduction d'une splénomégalie chez un patient souffrant de thalassémie, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un inhibiteur de jak2.
MA33672A 2008-08-05 2011-03-04 Procedes de traitement de la thalassemie MA32611B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8623308P 2008-08-05 2008-08-05
PCT/US2009/052544 WO2010017122A2 (fr) 2008-08-05 2009-08-03 Procédés de traitement de la thalassémie

Publications (1)

Publication Number Publication Date
MA32611B1 true MA32611B1 (fr) 2011-09-01

Family

ID=41581108

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33672A MA32611B1 (fr) 2008-08-05 2011-03-04 Procedes de traitement de la thalassemie

Country Status (20)

Country Link
US (1) US20110269721A1 (fr)
EP (1) EP2355827A2 (fr)
JP (1) JP2011530517A (fr)
KR (1) KR20110053347A (fr)
CN (1) CN102112131A (fr)
AU (1) AU2009279825A1 (fr)
BR (1) BRPI0917575A2 (fr)
CA (1) CA2732791A1 (fr)
CL (1) CL2011000242A1 (fr)
CO (1) CO6351728A2 (fr)
CR (1) CR20110115A (fr)
DO (1) DOP2011000044A (fr)
EC (1) ECSP11010847A (fr)
IL (1) IL211061A0 (fr)
MA (1) MA32611B1 (fr)
MX (1) MX2011001426A (fr)
NI (1) NI201100031A (fr)
RU (1) RU2011108563A (fr)
SV (1) SV2011003823A (fr)
WO (1) WO2010017122A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809614B1 (fr) 2004-04-08 2014-05-07 TargeGen, Inc. Inhibiteurs benzotriazine de kinases
CA2578283A1 (fr) 2004-08-25 2006-03-02 Targegen, Inc. Composes heterocycliques et methodes d'utilisation
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2012060847A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
NZ611654A (en) * 2010-12-03 2015-08-28 Ym Biosciences Australia Pty Treatment of jak2-mediated conditions
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN103664799A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2970205B1 (fr) * 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
MA44666A (fr) * 2016-04-15 2019-02-20 Epizyme Inc Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2
WO2018183923A1 (fr) * 2017-03-31 2018-10-04 Epizyme, Inc. Procédés d'utilisation d'inhibiteurs d'ehmt2
AU2018254577A1 (en) 2017-04-21 2019-12-05 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
CA3079412A1 (fr) * 2017-10-18 2019-04-25 Epizyme, Inc. Procedes d'utilisation d'inhibiteurs d'ehmt2 dans des immunotherapies
JP2021524835A (ja) 2018-04-05 2021-09-16 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Ａｘｌキナーゼ阻害剤およびその使用
MX2020010556A (es) 2018-04-13 2021-03-02 Sumitomo Pharma Oncology Inc Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
WO2020051571A1 (fr) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs de brd4-jak2
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
CN112778282B (zh) 2021-01-06 2022-07-22 温州医科大学 一种嘧啶类小分子化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191391B2 (ja) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤

Also Published As

Publication number Publication date
CA2732791A1 (fr) 2010-02-11
RU2011108563A (ru) 2012-09-10
KR20110053347A (ko) 2011-05-20
WO2010017122A3 (fr) 2010-04-08
CR20110115A (es) 2011-06-03
JP2011530517A (ja) 2011-12-22
NI201100031A (es) 2011-09-26
SV2011003823A (es) 2011-08-15
IL211061A0 (en) 2011-04-28
EP2355827A2 (fr) 2011-08-17
BRPI0917575A2 (pt) 2019-09-24
ECSP11010847A (es) 2011-07-29
AU2009279825A1 (en) 2010-02-11
CO6351728A2 (es) 2011-12-20
DOP2011000044A (es) 2011-04-30
CN102112131A (zh) 2011-06-29
WO2010017122A2 (fr) 2010-02-11
MX2011001426A (es) 2011-03-21
US20110269721A1 (en) 2011-11-03
CL2011000242A1 (es) 2011-04-08

Similar Documents

Publication Publication Date Title
MA32611B1 (fr) Procedes de traitement de la thalassemie
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA201100440A1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA200971053A1 (ru) Способы лечения кожных язв
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MY160006A (en) Thiazolopyridine sirtuin modulating compounds
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
EA201390815A1 (ru) Лечение jak2-опосредованных состояний
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
WO2011053822A3 (fr) Inhibition de notch pour le traitement et la prévention de l'obésité et du syndrome métabolique
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
MA32389B1 (fr) Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA201391591A1 (ru) Лечение множественной миеломы
EA201100255A1 (ru) 5-алкинилпиримидины
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
BR112013004850A2 (pt) tratamento de infarto do miocárdio usando antagonistas tgf-beta
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
EA201001749A1 (ru) Способ лечения недифференцированного артрита
MA34547B1 (fr) Traitement d'association pour traiter une infection par le vhc
EA200970436A1 (ru) Соединения карбамата для лечения депрессии